Table 2.
Patient characteristics based on NRF3 expression
| NRF3 negative (N=99) | NRF3 positive (N=45) | P-value | |
|---|---|---|---|
| Age | 51.5±12.56 | 49.5±0.71 | 0.7448 |
| Tumor size, n (%) | 0.5124 | ||
| <3 cm | 34 (34%) | 18 (40%) | |
| ≥3 cm | 65 (66%) | 27(60%) | |
| Lymph node status, n (%) | 0.0082＊＊ | ||
| Metastasis | 67(68%) | 20(44%) | |
| No Metastasis | 32(32%) | 25(56%) | |
| Stage, n (%) | 0.0365＊ | ||
| I | 9 (9%) | 5(11%) | |
| II | 51(51%) | 32(71%) | |
| III | 39(40%) | 8(18%) | |
| Histologic grade, n (%) | 0.2235 | ||
| I | 4(4%) | 1(2%) | |
| II | 73(74%) | 39(87%) | |
| III | 22(22%) | 5(11%) | |
| ER, n (%) | 0.5602 | ||
| Negative | 38(38%) | 15(33%) | |
| Positive | 61(62%) | 30(67%) | |
| PR, n (%) | 0.1259 | ||
| Negative | 51(52%) | 17(38%) | |
| Positive | 48(48%) | 28(62%) | |
| HER2, n (%) | 0.7697 | ||
| Negative | 68(69%) | 32(71%) | |
| Positive | 31(31%) | 13(29%) | |
| Subtype, n (%) | 0.7745 | ||
| TN | 15(15%) | 6(13%) | |
| Non-TN | 84(85%) | 39(87%) |
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; TN, triple-negative.